title: Continuous infusion of antisense phosphorothioate therapeutics.
abstract: Current therapy for acute myelogenous leukemia (AML) includes induction with Ara-C and an anthracycline, such as daunorubicin, idarubicin, or mitoxantrone. Unfortunately, most patients relapse from initial remission. Nearly one-fifth of early relapses experience treatment-related deaths. In addition, patients refractory to Ara-C die within months. Hence, new therapeutic agents must be identified capable of enhanced remission rates, diminished treatment-related mortality, or that can achieve remissions in refractory patients.
authors.affiliation: Departments of Pharmacology and Pharmaceutical Sciences, and The Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE.
authors.forename: P L
authors.initials: PL
authors.lastname: Iversen
authors.forename: B L
authors.initials: BL
authors.lastname: Copple
authors.forename: H K
authors.initials: HK
authors.lastname: Tewary
authors.forename: E
authors.initials: E
authors.lastname: Bayever
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop